261 related articles for article (PubMed ID: 34147404)
1. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
[TBL] [Abstract][Full Text] [Related]
2. Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S; Chevalier MF; Villier L; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
Eur Urol Open Sci; 2021 Dec; 34():79-82. PubMed ID: 34825225
[TBL] [Abstract][Full Text] [Related]
3. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
4. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
5. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
[TBL] [Abstract][Full Text] [Related]
6. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
7. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
8. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
Ikehara Y; Ikehara SK; Paulson JC
J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
[TBL] [Abstract][Full Text] [Related]
9. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.
Angata T; Varki A
J Biol Chem; 2000 Jul; 275(29):22127-35. PubMed ID: 10801860
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.
Lock K; Zhang J; Lu J; Lee SH; Crocker PR
Immunobiology; 2004; 209(1-2):199-207. PubMed ID: 15481154
[TBL] [Abstract][Full Text] [Related]
11. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
[TBL] [Abstract][Full Text] [Related]
12. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake.
Jones C; Virji M; Crocker PR
Mol Microbiol; 2003 Sep; 49(5):1213-25. PubMed ID: 12940982
[TBL] [Abstract][Full Text] [Related]
13. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.
Bochner BS
Clin Exp Allergy; 2009 Mar; 39(3):317-24. PubMed ID: 19178537
[TBL] [Abstract][Full Text] [Related]
14. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
16. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
17. Functional Inhibitory Siglec-6 Is Upregulated in Human Colorectal Cancer-Associated Mast Cells.
Yu Y; Blokhuis BRJ; Diks MAP; Keshavarzian A; Garssen J; Redegeld FA
Front Immunol; 2018; 9():2138. PubMed ID: 30294327
[TBL] [Abstract][Full Text] [Related]
18. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
[TBL] [Abstract][Full Text] [Related]
19. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
[TBL] [Abstract][Full Text] [Related]
20. High-affinity ligands of Siglec receptors and their therapeutic potentials.
Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
